MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $37.78 | Prev. Close $37.52 | Circuit Range N/A |
Day Range $36.63 - $38.04 | Year Range $4.81 - $44.77 | Volume 16,655 |
Average Traded $37.44 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $37.78 | $37.68 | +4.43% |
05-Feb-26 | $37.87 | $36.08 | -5.94% |
04-Feb-26 | $38.94 | $38.36 | -2.17% |
03-Feb-26 | $38.80 | $39.21 | +0.54% |
02-Feb-26 | $38.31 | $39.00 | +5.83% |
30-Jan-26 | $36.78 | $36.85 | +0.37% |
29-Jan-26 | $36.49 | $36.72 | +2.47% |